Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year

Elaine C. Siegfried; Eulalia Baselga; Marlies de Graaf; Eric L Simpson; Mark Boguniewicz; Carsten Flohr; Lawrence F. Eichenfield; Amy S. Paller; Michele Ramien; Xing-Hua Gao; Jiyoung Ahn; Korey Capozza; Yonghao Ma; Lauren Bates; Ana B. Rossi

doi:10.1093/bjd/ljag261

July 1, 2026British Journal of Dermatology

Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the long-term effectiveness of dupilumab in reducing symptoms of atopic dermatitis in children.
Patients aged 6 months to 17 years receiving dupilumab were monitored for one year.
Efficacy was measured using the Eczema Area and Severity Index and pruritus and sleep loss Visual Analog Scales.
Assessments were performed at baseline and across the treatment period.
The majority of participants maintained Eczema Area and Severity Index scores of ≤ 7 after one year.
Itch levels remained less than 4 on the SCORAD Pruritus VAS for most patients.
Sleep loss scores were also reported below 4 on the SCORAD sleep loss VAS, indicating significant overall improvement.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Shows sustained improvements in skin lesions and itch in pediatric patients, indicating effective long-term treatment.

Abstract

As atopic dermatitis signs and symptoms wax and wane, assessing severity scores over time best captures sustained response to treatment. We report that the majority of pediatric patients (6 months to 17 years) had sustained improvements in skin lesions (Eczema Area and Severity Index ≤ 7), itch (SCORING Atopic Dermatitis pruritus Visual Analog Scale [SCORAD Pruritus VAS < 4]), and sleep loss (SCORAD sleep loss VAS < 4) over one year of treatment with dupilumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Siegfried et al. (2026) studied this question.

synapsesocial.com/papers/6a47545e5c29257aa257a088 https://doi.org/10.1093/bjd/ljag261

View at Publisher

Ask AI

Bookmark

Share

Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading